Weekly paclitaxel/estramustine phosphate plus carboplatin administered either weekly or every 4 weeks in the treatment of hormone refractory prostate cancer (HRPC): A randomized phase II trial of the Minnie Pearl Cancer Research Network

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4659-4659
Author(s):  
A. A. Meluch ◽  
F. A. Greco ◽  
H. A. Burris ◽  
J. B. Erland ◽  
R. A. Khan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Research ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Research Network ◽  
Hormone Refractory Prostate Cancer ◽  
Estramustine Phosphate ◽  
Cancer Research Network ◽  
Randomized Phase Ii ◽  
Hormone Refractory

Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial

Oncology ◽  
2008 ◽  
Vol 74 (3-4) ◽  
pp. 223-228 ◽  
Author(s):  
Francesco Boccardo ◽  
Alessandra Rubagotti ◽  
Giario Conti ◽  
Michele Battaglia ◽  
Giorgio Cruciani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Randomized Phase Ii ◽  
Hormone Refractory
Sign in / Sign up

Export Citation Format

Share Document